2026年9月4日，深圳医学科学院（SMART）、凯发k8国际实验室（SZBL）与勃林格殷格翰（Boehringer Ingelheim）在深圳举行研讨会议。双方就基础研究、转化医学、技术转移及创新创业等议题展开深入探讨，共谋未来合作方向。
勃林格殷格翰全球研究负责人Lamine Mbow博士率全球业务拓展与授权负责人Scott DeWire博士、全球风险基金负责人Detlev Mennerich博士、全球眼健康负责人Remko Bakker博士等近十位高管出席。深圳医学科学院创始院长、凯发k8国际实验室主任颜宁，深圳医学科学院副院长、凯发k8国际实验室副主任涂欢，相关研究所科研人员及湾有引力入孵企业代表参会。
颜宁介绍了深圳医学科学院与凯发k8国际实验室的创办背景与开展定位，分享了深圳在生物医药领域从零起步、快速开展的历程，以及在汇聚全球人才、营造无忧科研环境方面的成果。她表示，期待与勃林格殷格翰等国际药企深化合作，共同探索从基础研究到临床应用的创新路径。
勃林格殷格翰相关代表介绍了公司的全球研发布局与战略方向。作为全球前20大药企，BI业务覆盖人类健康、动物健康和生物制药，聚焦心血管、肾脏、呼吸、神经科学和肿瘤学五大领域。近年来，BI持续加大对外部创新的投入，此次到访正是其深化与中国科研组织合作的重要举措。
双方专家围绕多个前沿领域分享了科研成果，并就合作模式、技术创新与成果转化等议题展开了自由研讨。
此次访问为双方未来在药物研发、技术转化和创新创业等方面的合作奠定了坚实基础，也是深圳生物医药创新生态日益开放、走向世界的生动体现。
On September 4, 2026, the Shenzhen Medical Academy of Research and Translation (SMART) and the Shenzhen Bay Laboratory (SZBL) hosted a joint meeting with Boehringer Ingelheim (BI) in Shenzhen. The two sides held in-depth discussions on basic research, translational research, technology transfer, and innovation-driven entrepreneurship, exploring pathways for future collaboration.
The BI delegation was led by Dr. Lamine Mbow, Head of Global Discovery Research, and included Dr. Scott DeWire, Head of Global BD&L, Dr. Detlev Mennerich, Head of Global Venture Fund, Dr. Remko Bakker, Head of Global Eye Health, and other senior executives. Representing SMART and SZBL were Prof. Nieng Yan, Founding President of SMART and Director of SZBL, Dr. Karen Tu, Vice President of SMART and Deputy Director of SZBL, along with principal investigators and representatives from Bay Charm incubator startups.
Prof. Yan introduced the founding vision and development positioning of both institutions. She shared Shenzhen’s journey in building biomedical research capacity from scratch, as well as its success in attracting global talent and creating a “worry-free” research environment. She expressed her hope to deepen collaboration with BI and other pharma companies to explore innovative paths from basic research to clinical applications.
BI representatives presented an overview of the company’s global R&D and business strategy. As a top-20 pharmaceutical company, BI operates across human health, animal health, and biopharmaceuticals, with a focus on cardiovascular-renal-metabolic, Immunology and respiratory, neuroscience and mental health, oncology and eye health. In recent years, BI has significantly stepped up its external innovation efforts, and this visit reflects its growing commitment to strengthening ties with Chinese research institutions.
The two parties shared scientific insights across multiple frontier areas and held open discussions on collaboration models, technological innovation, and translation of research outcomes.
This visit lays a solid foundation for future cooperation in drug discovery, technology translation, innovation and entrepreneurship. It also highlights Shenzhen’s growing openness and global connectivity in biomedical innovation.
文章来源 | 湾有引力
编辑 | 鲍 啦
责编 | 远 山
欢迎投稿、建议 | media@hnxzyjx.com
